Other primary ovarian failure
Methodology & AI Transparency ⓘ
Other primary ovarian failure Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Other primary ovarian failure—coded clinically as E28.39 across Menopause & HRT guidelines—combines or non-hormonal NK3-receptor in Other primary ovarian failure (E28.39: therapy) with structured follow-up of 17-Beta Estradiol & in Other primary ovarian failure (E28.39: FSH (Contextual)) (Symptom-guided physiological target (E28.39)).
- 2 Real-world patient consensus: Clinical coding for Other primary ovarian failure uses ICD-10 E28.39 across Menopause & HRT specialty care.
- 3 Typical cash cost range: Workup highlights for Other primary ovarian failure (E28.39): or non-hormonal NK3-receptor in Other primary ovarian failure (E28.39: therapy).
- 4 Top reported side effects / signs: Key Menopause & HRT biomarkers for Other primary ovarian failure (E28.39): TSH & HbA1c in Other primary ovarian failure (E28.39: Midlife Panel) & 17-Beta Estradiol & in Other primary ovarian failure (E28.39: FSH (Contextual)) (Symptom-guided physiological target (E28.39)).
Ask our AI Specialists anything about Other primary ovarian failure
What Is Other primary ovarian failure?
Other primary ovarian failure—coded clinically as E28.39 across Menopause & HRT guidelines—combines or non-hormonal NK3-receptor in Other primary ovarian failure (E28.39: therapy) with structured follow-up of 17-Beta Estradiol & in Other primary ovarian failure (E28.39: FSH (Contextual)) (Symptom-guided physiological target (E28.39)).
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Other primary ovarian failure (E28.39, Menopause & HRT) reflects accelerated trabecular osteoclast in Other primary ovarian failure (E28.39: turnover). longitudinal control is benchmarked via TSH & HbA1c in Other primary ovarian failure (E28.39: Midlife Panel).
Common Symptoms & Clinical Signs
- • Presentation of Other primary ovarian failure (E28.39): midsection body-composition shift, in Other primary ovarian failure (E28.39: joint stiffness, and)
- • Secondary Other primary ovarian failure clinical sign: vasomotor hot flashes, in Other primary ovarian failure (E28.39: sudden facial/chest warmth,)
- • Symptom flares in Other primary ovarian failure correlating with TSH & HbA1c in Other primary ovarian failure (E28.39: Midlife Panel) deviation outside TSH 0.8–2.5 mIU/L; HbA1c < 5.6% (E28.39)
- • Functional menopause & hrt impact requiring or non-hormonal NK3-receptor in Other primary ovarian failure (E28.39: therapy) evaluation (E28.39)
Other primary ovarian failure Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E28.39 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Menopause, Perimenopause & Hormone Therapy | NLM Clinical Tables |
| Diagnostic / Lab Marker: TSH & HbA1c in Other primary ovarian failure (E28.39: Midlife Panel) | TSH 0.8–2.5 mIU/L; HbA1c < 5.6% (E28.39) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 17-Beta Estradiol & in Other primary ovarian failure (E28.39: FSH (Contextual)) | Symptom-guided physiological target (E28.39) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: DEXA Bone Density in Other primary ovarian failure (E28.39: & Fasting ApoB) | T-Score > -1.0; ApoB < 75 mg/dL (E28.39) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Other primary ovarian failure
Treatment selection for Other primary ovarian failure depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Other primary ovarian failure)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| New Insights on Safety profile of telmisartan as single-drug treatment or combined with: What a 8,023-Participant Study Found The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities. Blood pressure. Supplement • 2008-06-15 • Randomized Controlled Trial | N = 8,023 | 96/100 | PMID 18705533 ↗ |
| New Insights on Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral: What a 1,835-Participant Study Found All doses of TX-001HR provided endometrial protection and were associated with an improved bleeding profile over time; older age, further last menstrual period, or lower baseline E2 may predict amenorrhea with TX-001HR. Menopause (New York, N.Y.) • 2020-04-15 • Phase III Randomized Trial | N = 1,835 | 96/100 | PMID 31913228 ↗ |
Other primary ovarian failure Patient Community & “People Like Me” Threads
Filter Other primary ovarian failure community threads and patient logs by age, biological sex, dosage, and treatment duration.